- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | HCW Biologics takes back rights to commercial-ready reagents | 2 | Seeking Alpha | ||
| 27.05. | HCW Biologics regains ex vivo rights to CAR-T therapy reagents | 1 | Investing.com | ||
| 27.05. | HCW Biologics Inc.: HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen | 1 | GlobeNewswire (USA) | ||
| 22.05. | HCW Biologics raises $4 million in private placement | 1 | Investing.com | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 21.05. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.05. | HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules | 5 | GlobeNewswire (USA) | ||
| 15.05. | Why Is HCW Biologics Stock Gaining Today? | 6 | Benzinga.com | ||
| 14.05. | HCW Biologics GAAP EPS of $0.37 beats by $0.81, revenue of $6.53M | 10 | Seeking Alpha | ||
| 14.05. | HCW Biologics Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.05. | HCW Biologics Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 14.05. | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | 603 | GlobeNewswire (Europe) | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| 14.05. | HCW Biologics Inc.: HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies | 330 | GlobeNewswire (Europe) | HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells BPD is a rare pediatric disease affecting underweight premature... ► Artikel lesen | |
| 30.04. | HCW Biologics Inc.: HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum | 1 | GlobeNewswire (USA) | ||
| 30.04. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.04. | HCW Biologics plant IND-Antrag für Krebsmedikament trotz hoher Barmittelverbrennung | 1 | Investing.com Deutsch | ||
| 27.04. | HCW Biologics plans 2027 IND filing for pancreatic cancer drug | 1 | Investing.com | ||
| 27.04. | HCW Biologics Inc.: HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors | 218 | GlobeNewswire (Europe) | Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in... ► Artikel lesen | |
| 24.04. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 23.04. | HCW Biologics Inc. - S-1, General form for registration of securities | - | SEC Filings |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,932 | -3,58 % | EQS-News: Evotec SE: Evotec ernennt Rui Wang zum Head of Global In Silico & AI | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Rui Wang zum Head of Global In Silico & AI
02.06.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| MODERNA | 41,190 | +0,12 % | Neue CAR-T-Erfolge bei Autoimmunerkrankungen: Warum Lösungen für Zelltherapien vor dem nächsten Wachstumsschub stehen könnten | ||
| VALNEVA | 2,331 | -0,64 % | Valneva im Höhenflug: Das Signal das die meisten Anleger noch nicht kennen - Meine Einschätzung für die neue Börsenwoche | ||
| PALATIN TECHNOLOGIES | 14,200 | +3,65 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,210 | +0,83 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,240 | -4,26 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,690 | +0,27 % | Arbutus Biopharma Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| XOMA ROYALTY | 36,200 | -1,09 % | Weekly Buzz: FDA Okays AstraZeneca's Saphnelo Pen, EC Clears Crinetics Pharmaceuticals' Acromegaly Drug, Soligenix Slumps, Ligand Snaps Up XOMA Royalty | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,580 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones | OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program... ► Artikel lesen | |
| NOVOCURE | 15,175 | +11,05 % | NovoCure Ltd - 8-K, Current Report | ||
| PHARMING | 1,115 | +0,54 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| CYTOKINETICS | 63,00 | +1,58 % | Cytokinetics, Incorporated: Cytokinetics bringt MYQORZO (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland | Auf den erfolgreichen Start in den USA folgt nun die Markteinführung in Europa
SOUTH SAN FRANCISCO, Kalifornien, und ZUG, Schweiz, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:... ► Artikel lesen | |
| TRAWS PHARMA | 1,380 | +0,73 % | Traws Pharma, Inc.: Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks | Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a... ► Artikel lesen |
Das Unternehmen HCW BIOLOGICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,31 % bei einem Aktienkurs von 1,625 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.